Mesoblast rises after FDA approves new potency assay for Ryoncil
Shares of Mesoblast MSB.AX rise as much as 5.1% to A$2.29, their biggest intraday pct gain since August 28.
Shares hit their highest level since September 9.
The biotech company gets US FDA approval to implement a new potency assay for release and stability monitoring of all new commercial products of Ryoncil, its mesenchymal stromal cell product.
Ryoncil is for the treatment of steroid-refractory acute graft versus host disease.
MESO•
